The last 30 years of Immuno-Oncology research have provided strong evidence that tumors do recognize the immune system and their development can be stopped or controlled long term. Given the impressive survival data over the past five years, it is not surprising that Immuno-Oncology is arguably the most exciting area in the advancement of science and patient care today.  However, with all research, there are plenty of challenges and to get a better understanding of this innovative approach to cancer research, we are pleased to welcome to the program, James Gulley, MD, PhD of the National CancerInstitute and Roy Baynes, MD, PhDat Merck Research Labs. Joining Drs Gulley and Baynes is Kate Woda, Director of theIO360 conference taking place at Columbia University Faculty House on June 29-30 in NYC. Host: Valerie Bowling, Producer, Pharma Talk Radio Guests: James Gulley, MD, PhD, Head, Immunotherapy Section, Director, Medical Oncology Service, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute Roy Baynes, MD, PhD, Senior Vice President, Global Clinical Development, Merck Research Labs and Kate Woda, Director, IO 360